First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?

S Wang, A Gao, J Liu, Y Sun - Cancer chemotherapy and pharmacology, 2018 - Springer
As the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with
activating epidermal growth factor receptor (EGFR) mutation, EGFR-tyrosine kinase …
被引用次数：14 相关文章

First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?

S Wang, A Gao, J Liu, Y Sun - Cancer Chemotherapy and …, 2018 - europepmc.org
As the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with
activating epidermal growth factor receptor (EGFR) mutation, EGFR-tyrosine kinase …

First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?

S Wang, A Gao, J Liu, Y Sun - Cancer Chemotherapy & …, 2018 - search.ebscohost.com
As the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with
activating epidermal growth factor receptor (EGFR) mutation, EGFR-tyrosine kinase …

First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?

S Wang, A Gao, J Liu, Y Sun - Cancer Chemotherapy and …, 2018 - search.proquest.com
As the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with
activating epidermal growth factor receptor (EGFR) mutation, EGFR-tyrosine kinase …

First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?

S Wang, A Gao, J Liu, Y Sun - Cancer chemotherapy …, 2018 - pubmed.ncbi.nlm.nih.gov
As the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with
activating epidermal growth factor receptor (EGFR) mutation, EGFR-tyrosine kinase …